Real-World Dose-Relativity, Tablet Burden, and Cost Comparison of Conversion Between Sevelamer Hydrochloride/Carbonate and Lanthanum Carbonate Monotherapies

Keith, Michael; Sibbel, Scott; Copley, John B.; Wilson, Rosamund; Brunelli, Steven M.

doi:10.1016/j.clinthera.2014.07.012

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cost estimates for PA21 treatment are currently absent, but are obligatory. Notably cost estimates in comparison to LC are important, as recent data suggest that converting dialysis patients from Sev to LC monotherapy offers cost-savings and a significant reduction in pill burden [70].…”

Section: Expert Opinionmentioning

confidence: 99%

Novel iron-containing phosphate binders for treatment of hyperphosphatemia

Schmid

Lederer²

2015

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

On the highly competitive market, where the 'ideal' PB is still unknown, novel substances that offer clear benefits over available drugs are desired. Although SO and FCH showed similar efficacy and safety compared to sevelamer, head-to-head studies with lanthanum carbonate are absent. Clinical 1-year data in a limited patient cohort suggested improved adherence for SO and a large randomized controlled trial showed significant reduction in hospitalizations and costs for FCH. Additional large randomized controlled trials have now to prove these possible advantages. Cost-effectiveness in comparison to other PB and the exclusion of significant harms under long-term treatment will determine the future use of both drugs.

show abstract

Section: Expert Opinionmentioning

confidence: 99%

Novel iron-containing phosphate binders for treatment of hyperphosphatemia

Schmid

Lederer²

2015

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis

Yu,

Sun,

Guo

2024

Renal Failure

View full text Add to dashboard Cite

Background Hyperphosphatemia occurs universally in end-stage renal disease(ESRD), and the attainment of target serum phosphate levels remains suboptimal with currently available phosphate binders. This meta-analysis aimed to evaluate the efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia. Methods Data sources included PubMed, Embase, Web of Science, and Cochrane Library. This meta-analysis included randomized controlled trials evaluating both the efficacy of tenapanor in reducing serum phosphate levels and its safety profile. The risk of bias was assessed using the Cochrane risk of bias tool for RCTs. The GRADE system was used to assess the overall certainty of evidence. A meta-analysis was carried out by using fixed effects ( I 2 values < 50%) or random effects ( I 2 values ≥ 50%) models to calculate MD with 95% CI for continuous outcome variables and RR with 95% CI for dichotomous variables. Publication bias was evaluated using funnel plots. Results A total of seven RCTs involving 877 individuals were included. The pooling analysis demonstrates that the reduction in mean serum phosphorus levels in the tenapanor group was significantly greater than that in the placebo group [MD= −1.06 mg/dl, 95% CI (−1.59, −0.53); I 2 = 83%, p < 0.0001]. The proportion of patients achieving a serum phosphorus level of < 5.5 mg/dL, along with the incidence of any adverse events (AEs) and gastrointestinal disorders, was higher in the tenapanor group compared to the placebo group. Conclusion Tenapanor has the potential to significantly reduce serum phosphorus levels and enhance the rate of achieving target levels compared to placebo, all while maintaining an acceptable safety and tolerability profile. Registration PROSPERO registration number CRD42024544531.

show abstract

Mobile and E-Healthcare: Recent Trends and Future Directions

Kher¹

2016

J Health Med Econ

View full text Add to dashboard Cite

In the past decade, wearable sensors and devices have evolved as key technological objects which have dramatically revolutionized the next generation healthcare solutions. This is the era of cut-throat competition filled with immense stress which leads to the detection of various diseases even in the people of early age. Moreover, people are becoming more health conscious in developed as well as developing countries. The miniaturization of sensors and devices and tendency of people to be physician-independent have lead the researchers across the globe to come up with numerous healthcare solutions which are not only ubiquitous but are affordable also. Wearable medical devices (WMDs) capable of monitoring some of the most common physiological parameters-pulse, blood oxygen saturation, 2 lead ECG, heart rhythm, skin temperature etc. have already been popular. Ambulatory and long-term health monitoring for elderly people is another aspect, particularly for countries like China and Japan where population aging is increasing. With the development of networks, collected health information can be sent to the cloud server of the nearest clinic or hospital. Doctors can then provide patients with medical advice. Thus, WMDs or WMD-based applications can help both patients and doctors in daily health monitoring. The paradigm has gradually shifted to the mobile health (mHealth) -an integration of ever advancing wireless communication, ubiquitous computing, and wearable device technologies. The mHealth can be regarded as the most advanced version of healthcare monitoring.

show abstract

Real-World Dose-Relativity, Tablet Burden, and Cost Comparison of Conversion Between Sevelamer Hydrochloride/Carbonate and Lanthanum Carbonate Monotherapies

Abstract: Converting patients with ESRD and hyperphosphatemia from SH/C to LC monotherapy offers potential drug cost savings and a significant reduction in the daily tablet burden, without compromising the effective management of serum phosphate levels.

Cited by 3 publications

References 26 publications

Novel iron-containing phosphate binders for treatment of hyperphosphatemia

Novel iron-containing phosphate binders for treatment of hyperphosphatemia

Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis

Mobile and E-Healthcare: Recent Trends and Future Directions

Contact Info

Product

Resources

About